Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?
Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephre...
Gespeichert in:
| Veröffentlicht in: | Urology (Ridgewood, N.J.) N.J.), 2009-10, Vol.74 (4), p.842-845 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 845 |
|---|---|
| container_issue | 4 |
| container_start_page | 842 |
| container_title | Urology (Ridgewood, N.J.) |
| container_volume | 74 |
| creator | Crépel, Maxime Isbarn, Hendrik Capitanio, Umberto Liberman, Daniel Jeldres, Claudio Sun, Maxine Shariat, Shahrokh F Widmer, Hugues Arjane, Philippe Graefen, Markus Montorsi, Francesco Patard, Jean-Jacques Perrotte, Paul Karakiewicz, Pierre I |
| description | Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint. |
| doi_str_mv | 10.1016/j.urology.2009.02.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_00410817v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090429509002349</els_id><sourcerecordid>67683857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-7db61b35179198c9a99de6eceafe46abbf6e0a270d8264a8054bdb9977ad2b403</originalsourceid><addsrcrecordid>eNqFkkFv1DAQhS0EokvhJ4BygRMJthPb8YVqVVoWacUiFc6W40y2XpI4tZNK-fc42qhIXDjNYb73ZvRmEHpLcEYw4Z9O2eRd645zRjGWGaYZJvkztCGMilRKyZ6jTWzgtKCSXaBXIZwwxpxz8RJdEMlpSTndoB9fHIRkZ8O4mFmT3E3VOA-QbJsGzJgcerM2DtNoXBfhbTOCT77DcO9dn4ZBe9sfo84fwc9Xr9GLRrcB3qz1Ev26vfl5vUv3h6_frrf71DBGxlTUFSdVzoiQRJZGailr4GBAN1BwXVUNB6ypwHXcs9AlZkVVV1IKoWtaFTi_RB_Pvve6VYO3nfazctqq3XavbB_AdwrjguCSiEcS8Q9nfPDuYYIwqs4GA22re3BTUFzwMi-ZiCA7g8a7EDw0T-YEqyV5dVJr8mpJXmGqYvJR924dMFUd1H9Va9QReL8COhjdNl73xoYnji5mUrDIXZ05iOk9WvAqGAu9gdr6eBFVO_vfVT7_42Ba29s49DfMEE5u8n08jSIqRIG6W95k-ZJYMM0Lmf8B2-a5cQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67683857</pqid></control><display><type>article</type><title>Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Crépel, Maxime ; Isbarn, Hendrik ; Capitanio, Umberto ; Liberman, Daniel ; Jeldres, Claudio ; Sun, Maxine ; Shariat, Shahrokh F ; Widmer, Hugues ; Arjane, Philippe ; Graefen, Markus ; Montorsi, Francesco ; Patard, Jean-Jacques ; Perrotte, Paul ; Karakiewicz, Pierre I</creator><creatorcontrib>Crépel, Maxime ; Isbarn, Hendrik ; Capitanio, Umberto ; Liberman, Daniel ; Jeldres, Claudio ; Sun, Maxine ; Shariat, Shahrokh F ; Widmer, Hugues ; Arjane, Philippe ; Graefen, Markus ; Montorsi, Francesco ; Patard, Jean-Jacques ; Perrotte, Paul ; Karakiewicz, Pierre I</creatorcontrib><description>Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/j.urology.2009.02.013</identifier><identifier>PMID: 19628262</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cancer ; Carcinoma, Renal Cell ; Carcinoma, Renal Cell - classification ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - surgery ; Female ; Human health and pathology ; Humans ; Kidney Neoplasms ; Kidney Neoplasms - classification ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Life Sciences ; Male ; Medical sciences ; Middle Aged ; Nephrectomy ; Nephrectomy - methods ; Nephrology. Urinary tract diseases ; Nephrons ; Surgery ; Survival Rate ; Treatment Outcome ; Urology ; Urology and Nephrology ; Young Adult</subject><ispartof>Urology (Ridgewood, N.J.), 2009-10, Vol.74 (4), p.842-845</ispartof><rights>2009</rights><rights>2009 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-7db61b35179198c9a99de6eceafe46abbf6e0a270d8264a8054bdb9977ad2b403</citedby><cites>FETCH-LOGICAL-c551t-7db61b35179198c9a99de6eceafe46abbf6e0a270d8264a8054bdb9977ad2b403</cites><orcidid>0000-0001-9032-6538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urology.2009.02.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22009975$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19628262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-00410817$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Crépel, Maxime</creatorcontrib><creatorcontrib>Isbarn, Hendrik</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Liberman, Daniel</creatorcontrib><creatorcontrib>Jeldres, Claudio</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Shariat, Shahrokh F</creatorcontrib><creatorcontrib>Widmer, Hugues</creatorcontrib><creatorcontrib>Arjane, Philippe</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Patard, Jean-Jacques</creatorcontrib><creatorcontrib>Perrotte, Paul</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><title>Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Carcinoma, Renal Cell</subject><subject>Carcinoma, Renal Cell - classification</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - surgery</subject><subject>Female</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Kidney Neoplasms</subject><subject>Kidney Neoplasms - classification</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - surgery</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrectomy</subject><subject>Nephrectomy - methods</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephrons</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Urology</subject><subject>Urology and Nephrology</subject><subject>Young Adult</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkkFv1DAQhS0EokvhJ4BygRMJthPb8YVqVVoWacUiFc6W40y2XpI4tZNK-fc42qhIXDjNYb73ZvRmEHpLcEYw4Z9O2eRd645zRjGWGaYZJvkztCGMilRKyZ6jTWzgtKCSXaBXIZwwxpxz8RJdEMlpSTndoB9fHIRkZ8O4mFmT3E3VOA-QbJsGzJgcerM2DtNoXBfhbTOCT77DcO9dn4ZBe9sfo84fwc9Xr9GLRrcB3qz1Ev26vfl5vUv3h6_frrf71DBGxlTUFSdVzoiQRJZGailr4GBAN1BwXVUNB6ypwHXcs9AlZkVVV1IKoWtaFTi_RB_Pvve6VYO3nfazctqq3XavbB_AdwrjguCSiEcS8Q9nfPDuYYIwqs4GA22re3BTUFzwMi-ZiCA7g8a7EDw0T-YEqyV5dVJr8mpJXmGqYvJR924dMFUd1H9Va9QReL8COhjdNl73xoYnji5mUrDIXZ05iOk9WvAqGAu9gdr6eBFVO_vfVT7_42Ba29s49DfMEE5u8n08jSIqRIG6W95k-ZJYMM0Lmf8B2-a5cQ</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Crépel, Maxime</creator><creator>Isbarn, Hendrik</creator><creator>Capitanio, Umberto</creator><creator>Liberman, Daniel</creator><creator>Jeldres, Claudio</creator><creator>Sun, Maxine</creator><creator>Shariat, Shahrokh F</creator><creator>Widmer, Hugues</creator><creator>Arjane, Philippe</creator><creator>Graefen, Markus</creator><creator>Montorsi, Francesco</creator><creator>Patard, Jean-Jacques</creator><creator>Perrotte, Paul</creator><creator>Karakiewicz, Pierre I</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9032-6538</orcidid></search><sort><creationdate>20091001</creationdate><title>Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?</title><author>Crépel, Maxime ; Isbarn, Hendrik ; Capitanio, Umberto ; Liberman, Daniel ; Jeldres, Claudio ; Sun, Maxine ; Shariat, Shahrokh F ; Widmer, Hugues ; Arjane, Philippe ; Graefen, Markus ; Montorsi, Francesco ; Patard, Jean-Jacques ; Perrotte, Paul ; Karakiewicz, Pierre I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-7db61b35179198c9a99de6eceafe46abbf6e0a270d8264a8054bdb9977ad2b403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Carcinoma, Renal Cell</topic><topic>Carcinoma, Renal Cell - classification</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - surgery</topic><topic>Female</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Kidney Neoplasms</topic><topic>Kidney Neoplasms - classification</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - surgery</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrectomy</topic><topic>Nephrectomy - methods</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephrons</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Urology</topic><topic>Urology and Nephrology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crépel, Maxime</creatorcontrib><creatorcontrib>Isbarn, Hendrik</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Liberman, Daniel</creatorcontrib><creatorcontrib>Jeldres, Claudio</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Shariat, Shahrokh F</creatorcontrib><creatorcontrib>Widmer, Hugues</creatorcontrib><creatorcontrib>Arjane, Philippe</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Patard, Jean-Jacques</creatorcontrib><creatorcontrib>Perrotte, Paul</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crépel, Maxime</au><au>Isbarn, Hendrik</au><au>Capitanio, Umberto</au><au>Liberman, Daniel</au><au>Jeldres, Claudio</au><au>Sun, Maxine</au><au>Shariat, Shahrokh F</au><au>Widmer, Hugues</au><au>Arjane, Philippe</au><au>Graefen, Markus</au><au>Montorsi, Francesco</au><au>Patard, Jean-Jacques</au><au>Perrotte, Paul</au><au>Karakiewicz, Pierre I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>74</volume><issue>4</issue><spage>842</spage><epage>845</epage><pages>842-845</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19628262</pmid><doi>10.1016/j.urology.2009.02.013</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-9032-6538</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-4295 |
| ispartof | Urology (Ridgewood, N.J.), 2009-10, Vol.74 (4), p.842-845 |
| issn | 0090-4295 1527-9995 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_00410817v1 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Cancer Carcinoma, Renal Cell Carcinoma, Renal Cell - classification Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Female Human health and pathology Humans Kidney Neoplasms Kidney Neoplasms - classification Kidney Neoplasms - pathology Kidney Neoplasms - surgery Life Sciences Male Medical sciences Middle Aged Nephrectomy Nephrectomy - methods Nephrology. Urinary tract diseases Nephrons Surgery Survival Rate Treatment Outcome Urology Urology and Nephrology Young Adult |
| title | Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A32%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20Histologic%20Subtype%20Affect%20Oncologic%20Outcomes%20After%20Nephron-sparing%20Surgery?&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Cr%C3%A9pel,%20Maxime&rft.date=2009-10-01&rft.volume=74&rft.issue=4&rft.spage=842&rft.epage=845&rft.pages=842-845&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/j.urology.2009.02.013&rft_dat=%3Cproquest_hal_p%3E67683857%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67683857&rft_id=info:pmid/19628262&rft_els_id=1_s2_0_S0090429509002349&rfr_iscdi=true |